Skip to main content

PerkinElmer Value Stock - Dividend - Research Selection

Perkinelmer

ISIN: US7140461093 , WKN: 850943

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Revvity Earnings: What To Look For From RVTY

2026-05-04
Life sciences company Revvity (NYSE:RVTY) will be reporting earnings this Tuesday before market hours. Here’s what you need to know.

Revvity to Report Q1 Earnings: What's in Store for the Stock?

2026-05-04
RVTY heads into Q1 earnings with Diagnostics strength and Life Sciences stabilization, but China pressures and weak academic demand may temper near-term growth.

Packaging Corp Of America To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday

2026-05-04
Needham analyst Rick Patel maintained a Buy rating. Steven Madden shares closed at $47.27 on Friday. Top analysts change outlook on BTSG, CELC, ESS, CORT, PKG, PRU, RVTY, and SHOO. See how they rate these stocks on Benzinga's analyst ratings page.

Baird Maintains Outperform on Revvity, Lowers Price Target to $125

2026-05-04
Baird analyst Catherine Ramsey maintains Revvity (NYSE:RVTY) with a Outperform and lowers the price target from $129 to $125.

Revvity Shareholders Re-Elect Board, Approve Bylaw Change; Exec Stock Retention Proposal Fails

2026-05-04
Revvity (NYSE:RVTY) held its 2026 Annual Meeting of Shareholders virtually via live audio webcast, with General Counsel and Secretary Joel Goldberg serving as host and President and CEO Prahlad Singh presiding over the formal business of the meeting. Goldberg reported that holders of approximately

Revvity Board Declares Quarterly Dividend

2026-04-30
WALTHAM, Mass., April 30, 2026--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 7, 2026 to all shareholders of record at the close of business on July 17, 2026.

9 Health Care Stocks With Whale Alerts In Today's Session

2026-04-24

These S&P500 stocks are moving in today's session

2026-04-23
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.

What's going on in today's session: S&P500 movers

2026-04-23
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.

3 Reasons to Avoid RVTY and 1 Stock to Buy Instead

2026-04-22
Revvity currently trades at $94.26 per share and has shown little upside over the past six months, posting a small loss of 1.5%. The stock also fell short of the S&P 500’s 6.1% gain during that period.